Pathogenic role of CXCR7 in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 62, Issue 11, 2010, Pages 3211-3220

  Watanabe, Kaori ^a   Penfold, Mark E T ^b   Matsuda, Akio ^c   Ohyanagi, Naho ^a   Kaneko, Kayoko ^a   Miyabe, Yoshishige ^a   Matsumoto, Kenji ^c   Schall, Thomas J ^b   Miyasaka, Nobuyuki ^a   Nanki, Toshihiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b ChemoCentryx Inc   (United States)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CCX 733; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; INTERLEUKIN 1BETA; PLERIXAFOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; UMBILICAL VEIN;

ANALYSIS OF VARIANCE; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTORS, CXCR; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; UMBILICAL VEINS;

EID: 78249284977     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27650     Document Type: Article

References (45)

1. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR,. Macrophages in rheumatoid arthritis. Arthritis Res 2000; 2: 189 - 202.
2. Ritchlin C,. Fibroblast biology: effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2000; 2: 356 - 60.
3. Szekanecz Z, Koch AE,. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007; 3: 635 - 43.
4. Szekanecz Z, Koch AE,. Vascular involvement in rheumatic diseases: ?vascular rheumatology.? Arthritis Res Ther 2008; 10: 224.
5. Taylor PC, Sivakumar B,. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005; 17: 293 - 8.
6. Szekanecz Z, Strieter RM, Kunkel SL, Koch AE,. Chemokines in rheumatoid arthritis. Springer Semin Immunopathol 1998; 20: 115 - 32.
7. + T cell activation. J Immunol 2000; 164: 5010 - 4.
8. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z,. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002; 6: 357 - 76.
9. Kanbe K, Takagishi K, Chen Q,. Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum 2002; 46: 130 - 7.
10. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-β1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 2000; 165: 3423 - 9.
11. + T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000; 165: 6590 - 8.
12. Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 2003; 170: 2147 - 52.
13. Bradfield PF, Amft N, Vernon-Wilson E, Exley AE, Parsonage G, Rainger GE, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum 2003; 48: 2472 - 82.
14. Blades MC, Ingegnoli F, Wheller SK, Manzo A, Wahid S, Panayi GS, et al. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID mice. Arthritis Rheum 2002; 46: 824 - 36. (Pubitemid 34214266)
15. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ,. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1-and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 2001; 107: 305 - 15.
16. Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G,. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 2004; 199: 244 - 51.
17. Salcedo R, Oppenheim JJ,. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003; 10: 359 - 70.
18. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829 - 33.
19. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-γ receptor-deficient mice. J Immunol 2001; 167: 4686 - 92.
20. Tamamura H, Fujisawa M, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett 2004; 569: 99 - 104.
21. De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, Vermeire K, et al. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther 2005; 7: R1208 - 20.
22. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005; 280: 35760 - 6.
23. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201 - 13.
24. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007; 104: 15735 - 40.
25. Wang J, Shiozawa Y, Wang Y, Jung Y, Pienta KJ, Mehra R, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283: 4283 - 94.
26. Mazzinghi B, Ronconi E, Lazzeri E, Sagrinati C, Ballerini L, Angelotti ML, et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med 2008; 205: 479 - 90.
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315 - 24.
28. Matsuda A, Fukuda S, Matsumoto K, Saito H,. Th1/Th2 cytokines reciprocally regulate in vitro pulmonary angiogenesis via CXC chemokine synthesis. Am J Respir Cell Mol Biol 2008; 38: 168 - 75.
29. Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD,. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. J Pharmacol Exp Ther 2000; 292: 31 - 7.
30. Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T,. Effect of a small molecule inhibitor of nuclear factor-B nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005; 7: R1348 - 59.
31. Wood NC, Dickens E, Symons JA, Duff GW,. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin Immunol Immunopathol 1992; 62: 295 - 300.
32. De Clercq E,. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 2005; 5: 805 - 24.
33. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N,. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009; 75: 1240 - 7.
34. + cells. J Leukoc Biol 2008; 84: 1130 - 40.
35. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44: 2055 - 64.
36. Choi ST, Kim JH, Seok JY, Park YB, Lee SK,. Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 2009; 28: 333 - 7.
37. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 2007; 104: 14759 - 64.
38. Meijer J, Ogink J, Roos E,. Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer 2008; 99: 1493 - 501.
39. McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2: 175 - 82.
40. Nanki T, Takada K, Komano Y, Morio T, Kanegane H, Nakajima A, et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2009; 11: R149.
41. Nanki T, Lipsky PE,. Stimulation of T-Cell activation by CXCL12/stromal cell derived factor-1 involves a G-protein mediated signaling pathway. Cell Immunol 2001; 214: 145 - 54.
42. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635 - 8.
43. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393: 591 - 4.
44. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR,. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595 - 9.
45. Infantino S, Moepps B, Thelen M,. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J Immunol 2006; 176: 2197 - 207.